Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer

NCT05914610 | Not Yet Recruiting Phase 3

• 1 other identifier: FUGES-028
• Study Type: interventional
• Target: 100
• Locations: 0 countries
• Sites: N/A

Brief Summary

To investigate the clinical efficacy and safety of envollizumab combined with fruquintinib and SOX versus SOX in conversion therapy for patients with Her-2 negative, unresectable locally advanced gastric cancer.

Conditions

Gastric Cancer

Outcome Measures

Primary Outcomes (1)

• Surgical conversion rate

  Defined as the proportion of patients who have undergone surgical resection after multidisciplinary assessment after completing 4-6 cycles of conversion therapy

  2-3 months

Secondary Outcomes (10)

• Pathological complete response (pCR)

  4 months

• Median disease free survival (DFS) time

  3 years

• 1-year DFS rate

  1 year

• 3-year DFS rate

  3 years

• Objective response rate (ORR)

  4 months

Study Arms (2)

Envolimab + fruquinitinib +SOX regimen

EXPERIMENTAL

Drug: Envolimab; Drug: Fruquintinib; Drug: Oxaliplatin; Drug: Tegafur

SOX regimen

ACTIVE COMPARATOR

Drug: Oxaliplatin; Drug: Tegafur

Interventions

Envolimab DRUG

Envolizumab 300mg, D1, ih, Q3W 4-6cycles

Envolimab + fruquinitinib +SOX regimen

Fruquintinib DRUG

Fruquinitinib 3mg/d, QD, PO, D1-D14, Q3W 4-6cycles

Envolimab + fruquinitinib +SOX regimen

Oxaliplatin DRUG

Oxaliplatin 130 mg/m2, ivgtt 0-2h, D1, Q3W 4-6cycles

Envolimab + fruquinitinib +SOX regimen; SOX regimen

Tegafur DRUG

Tegafur was calculated according to body surface area , P.O., bid, d1-d14#And the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time Q3W 4-6cycles

Envolimab + fruquinitinib +SOX regimen; SOX regimen

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age: 18-75 years of age;
• Pathological (including histological or cytological) confirmation of gastric adenocarcinoma;
• Before surgery, CT/MRI, PET-CT, if necessary, laparoscopic exploration to determine the clinical stage of T4bN0M0 and TanyN2-3M0, and determined by researchers that the local advanced patients can not be resectable;
• At least one measurable detected by CT examination in accordance with the RECIST1.1
• ECOG#Eastern Cooperative Oncology Group#PS#Performance Status#:0-1 scores;
• The expected survival time is more than 3 months
• The main organ function is normal, which should meet the following criteria:
• #1#blood routine examination standards should be met#no blood transfusion within 14 days#
• a.HB≥ 100g/L b. WBC≥3×109/L c. ANC≥1.5×109/L d. PLT≥100×109/L #2#biochemical examination shall comply with the following criteria#
• BIL#1.5 normal upper limit ULN
• ALT and AST#2.5 ULN
• Cr≤1 ULN#CCR#creatinine clearance rate##60ml/min(Cockcroft Gault formula)
• Women of childbearing age must have a pregnancy test in 7 days before entering the group (in serum), and the results were negative, and willing to use appropriate contraception during the study period and the last 8 weeks after giving drug test; men should have the surgical sterilization, or adopt the appropriate contraceptive methods during the test and the last 8 weeks after giving drug test#
• No other clinical studies were conducted before and during the treatment
• Participants is willing to participate in this study, sign the informed consent, have good compliance, cooperate with follow-up

You may not qualify if:

• Imaging or intraoperative exploration found patients with peritoneum, liver, lung and other distant metastases
• Patients with allergies or suspected allergies to study drugs or similar drugs
• Confirmed HER-2 positive patients
• Other malignancies in the past 5 years, except basal cell or squamous cell carcinoma of the skin after radical surgery, or carcinoma in situ of the cervix
• Live vaccine was administered within 4 weeks prior to enrolling or possibly during the study period
• Had an active autoimmune disease or a history of autoimmune disease within 4 weeks prior to enrollment
• Past recipients of allogeneic bone marrow transplants or organ transplants
• Patient has any current disease or condition that affects drug absorption, or the patient is unable to take the drug orally
• The blood pressure of patients with hypertension cannot be reduced to the normal range by the one antihypertensive drugs (systolic pressure ≥150 mmHg, diastolic pressure ≥100 mmHg) or hard to controled by two or more antihypertensive drugs
• Patients are positive of urine protein (urine protein detection 2+ or above, or 24 hours urine protein quantitative \>1.0g)
• The patient currently has gastrointestinal diseases such as active gastric and duodenal ulcers, ulcerative colitis, or active bleeding from unresectosed tumors, or other conditions determined by researchers that may cause gastrointestinal bleeding or perforation
• Patients with significant evidence or history of bleeding tendency within 3 months prior to enrollment (bleeding within 3 months \>30 mL, hematemesis, black stool, blood in stool), hemoptysis (within 4 weeks \>5 mL fresh blood) or a thromboembolic event (including stroke and/or transient ischemic attack) within 12 months
• Cardiovascular disease of significant clinical significance, including but not limited to acute myocardial infarction, severe/unstable angina, or coronary artery bypass grafting within 6 months prior to enrollment; New York Heart Association (NYHA) Grades for Congestive Heart Failure more than class II ; Ventricular arrhythmias requiring medical treatment; An electrocardiogram (ECG) showed a QT c interval ≥480 milliseconds
• Active or uncontrolled severe infection (≥CTCAE grade 2 infection)
• A history of human immunodeficiency virus (HIV) infection or clinically significant liver disease, including viral hepatitis \[active HBV infection must be ruled out as a known carrier of hepatitis B virus (HBV), i.e. positive HBV DNA (\>1×104 copies /mL or \>2000 IU/ml); known hepatitis C virus infection (HCV) and HCV RNA positive (\>1×103 copies /mL), or other hepatitis, cirrhosis\]

Sponsors & Collaborators

• Fujian Medical University: lead

MeSH Terms

Conditions

Stomach Neoplasms

Interventions

HMPL-013; Oxaliplatin; Tegafur

Condition Hierarchy (Ancestors)

Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Stomach Diseases

Intervention Hierarchy (Ancestors)

Coordination Complexes; Organic Chemicals; Fluorouracil; Uracil; Pyrimidinones; Pyrimidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Clinical Professor

Study Record Dates

• First Submitted: May 27, 2023
• First Posted: June 22, 2023
• Study Start: September 1, 2023
• Primary Completion: July 30, 2025
• Study Completion (Estimated): July 30, 2028
• Last Updated: August 25, 2023

Record last verified: 2023-08